GlassScriptPhysician profile
Binny Koshy
NPI 1114925708
$170,317.63
in general payments reported to CMS, 2019-2025
28 companies · $9,850 in 2025
The $9,850 reported for 2025 was more than what 95% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $14K · 2021: $76K · 2022: $31K · 2023: $34K · 2024: $4,337 · 2025: $9,850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $6,407 · Consulting Fee: $6,208 · Travel and Lodging: $1,432 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,550.00 |
| Food and Beverage | $6,407.05 |
| Consulting Fee | $6,207.50 |
| Travel and Lodging | $1,432.44 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $124,245.22 | 2019-2025 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $27,775.68 | 2021-2025 | Benlysta, Jesduvroq |
| Ardelyx, INC. | $8,357.56 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Vifor Pharma, INC. | $4,268.36 | 2019-2024 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $714.51 | 2021-2025 | |
| Amgen INC. | $675.97 | 2019-2025 | Tavneos, Krystexxa, Aranesp |
| Otsuka America Pharmaceutical, INC. | $634.46 | 2019-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $553.26 | 2019-2024 | Velphoro |
| Travere Therapeutics, INC. | $452.08 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $350.80 | 2023-2025 | Tarpeyo |
| Akebia Therapeutics INC | $347.53 | 2019-2025 | Vafseo |
| Mallinckrodt Hospital Products INC. | $282.98 | 2021-2025 | Acthar, Terlivaz |
| Janssen Scientific Affairs, LLC | $245.28 | 2019-2024 | Xarelto |
| Opko Pharmaceuticals, LLC | $222.37 | 2019-2025 | Rayaldee |
| Horizon Therapeutics Plc | $201.66 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $199.47 | 2023-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $175.75 | 2019-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $146.83 | 2023-2025 | |
| Intuity Medical INC | $121.24 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $94.28 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.60 | 2024-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $35.18 | 2023 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $29.60 | 2023 | Gattex |
| Renalytix Ai, INC. | $24.00 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Fresenius USA Manufacturing, INC. | $22.31 | 2025 | |
| Mallinckrodt Enterprises LLC | $20.18 | 2019 | |
| Aurinia Pharma U.S., INC. | $19.83 | 2023 | Lupkynis |
| Daiichi Sankyo INC. | $19.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Binny Koshy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.